Bi, Silei <br/><br/>
Napabucasin (BBI608) eliminate AML cells in vitro and in vivo via inhibition of Stat3 pathway and induction of DNA damage.  [electronic resource] 

 -  European journal of pharmacology  Jul 2019 
 - 252-261 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1879-0712 
<br/><br/><label>Standard No.: </label>10.1016/j.ejphar.2019.05.020  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis--drug effects<br/>Benzofurans--pharmacology<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>DNA Damage<br/>Dose-Response Relationship, Drug<br/>Drug Resistance, Neoplasm--drug effects<br/>Female<br/>G1 Phase Cell Cycle Checkpoints--drug effects<br/>Humans<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Male<br/>Membrane Potential, Mitochondrial--drug effects<br/>Mice<br/>Middle Aged<br/>Naphthoquinones--pharmacology<br/>Resting Phase, Cell Cycle--drug effects<br/>STAT3 Transcription Factor--metabolism<br/>Time Factors<br/>Xenograft Model Antitumor Assays<br/>Young Adult